Paucity or low expression of PD-L1 on tumor cells is a well-defined factor associated with primary resistance to anti-PD-1 antibody treatment [26, 27], while high expression of PD-L1 commonly indicates a better clinical response [28]. The gene discussed is PDCD1; the disease is neoplasm.